Perceiv was founded to close this gap.
The last decade has brought unprecedented breakthroughs in understanding and treating complex neurological diseases like Alzheimer's. Yet, for every scientific leap forward, a logistical hurdle stands in the way, preventing these life-changing therapies from reaching the patients who need them most.
Treatment is often confined to a few specialty centers, creating geographic barriers and long waitlists. Many eligible patients in less experienced specialized settings may face added challenges as limited resources and training hinder local delivery of these therapies.
Without a standardized patient management framework, the quality and safety of care can vary dramatically from one clinic to another, creating risks that can directly impact patient health outcomes.
The intense safety monitoring required for these therapies presents a challenge for many clinical practices, creating a risk of missed safety events or suboptimal management of patient health outcomes.
We believe that a patient's access to groundbreaking treatment shouldn't be limited by the complexity of its delivery.
Our flagship platform, Foresight™, is a secure, intelligent coordination center designed for the realities of modern neurological care. It transforms the entire treatment journey, from patient identification and eligibility screening to long-term safety monitoring, into a seamless, standardized process.
Our mission is to ensure that every patient can access the latest medical breakthroughs safely, efficiently, and equitably. We are building the digital backbone that will support the next generation of neurological treatments, starting with Alzheimer's disease.
Foresight™, a therapy-agnostic platform by Perceiv Research Inc., is purpose-built to close these care gaps. It provides the essential infrastructure for standardized patient management practices, disease education, and patient health outcomes management, ensuring every patient can receive the highest standard of care.
Foresight™ is a secure, ISO/IEC 27001:2022 certified and multi-region compliant (HIPAA, GDPR, PIPEDA) cloud platform that enables a new standard of care for all Alzheimer's DMTs.
A Standardized ARIA and Safety Monitoring Module
An Automated Clinical Workflow Engine
A Collaborative Care Portal
Post-Market Safety & Adherence Insights
Launching Canadian Alzheimer's REadiness (CARE), a Nationwide Physician-led Initiative Paving the Way for Disease-Modifying Therapies in Alzheimer's Disease
October 16, 2025 | Calgary, Canada | Poster
October 14, 2024 | Montreal, Canada | Press release
November 28, 2023 | Montreal, Canada | Press release
June 21, 2023 | Toronto, Canada | Annoucement
January 17, 2023 | Boston, USA | Annoucement
Find all our past news and announcements in our Newsroom!